Verified Nov 2026
Other
·

Lexington, Massachusetts
·
Since 2007
Dicerna Pharmaceuticals develops RNA interference-based therapeutics targeting liver and genetic diseases. Headquartered in Lexington, Massachusetts and founded in 2007, the company operates with 50–100 employees and estimated revenue of $100–250 million. Dicerna became a wholly owned subsidiary of Novo Nordisk A/S in December 2021 following a $3.3 billion acquisition. In January 2025, Roche partnered with Dicerna on a hepatitis B gene-silencing drug program.
Dicerna Pharmaceuticals Inc at a glance
Revenue
$100-250M
Est. band
Employees
50-100
Founded
2007
Headquarters
Lexington, Massachusetts
Industries
Automotive
Electric Vehicles
Medical
Overview
Dicerna Pharmaceuticals develops RNA interference-based therapeutics targeting liver and genetic diseases. Headquartered in Lexington, Massachusetts and founded in 2007, the company operates with 50–100 employees and estimated revenue of $100–250 million. Dicerna became a wholly owned subsidiary of Novo Nordisk A/S in December 2021 following a $3.3 billion acquisition. In January 2025, Roche partnered with Dicerna on a hepatitis B gene-silencing drug program.
At a glance
Attribute | Detail |
|---|---|
Founded | 2007 |
Headquarters | Lexington, Massachusetts |
Employees | 50-100 |
Revenue | $100-250M (estimated) |
What Dicerna Pharmaceuticals Inc makes
Dicerna utilizes its proprietary GalXC™ platform and expanded GalXC-Plus™ platform to develop RNAi-based pharmaceuticals that silence disease-causing genes, with applications in primary hyperoxaluria, chronic hepatitis B, and alcohol use disorder.
Latest developments
2026-05-28 — EnPlusOne Adds Former Dicerna Executive Jim Weissman to Board as RNA Manufacturing Efforts Expand | citybiz (citybiz.co)
2025-11-06 — Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (quantisnow.com)
2025-01-05 — Roche Partners with Dicerna for Hepatitis B Gene-Silencing Drug - MedPath Trial (medpath.com)
Facilities
Dicerna Pharmaceuticals Inc is headquartered in Lexington, Massachusetts. Public sources also reference these locations:
Denmark — lifescicre.com
Company details
The company maintains active pharmaceutical partnerships, including a 2025 collaboration with Roche on hepatitis B therapeutics. Dicerna Pharmaceuticals Inc was founded in 2007, has an estimated 50-100 employees, and is headquartered in Lexington, Massachusetts.
Frequently asked questions
What does Dicerna Pharmaceuticals Inc do?
Dicerna Pharmaceuticals develops RNA interference-based therapeutics targeting liver and genetic diseases. Headquartered in Lexington, Massachusetts and founded in 2007, the company operates with 50–100 employees and estimated revenue of $100–250 million. Dicerna became a wholly owned subsidiary of Novo Nordisk A/S in December 2021 following a $3.3 billion acquisition. In January 2025, Roche partnered with Dicerna on a hepatitis B gene-silencing drug program.
Where is Dicerna Pharmaceuticals Inc headquartered?
Dicerna Pharmaceuticals Inc is headquartered in Lexington, Massachusetts.
When was Dicerna Pharmaceuticals Inc founded?
Dicerna Pharmaceuticals Inc was founded in 2007.
How big is Dicerna Pharmaceuticals Inc?
Dicerna Pharmaceuticals Inc has an estimated 50-100 employees, with revenue in the $100-250M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
